| 117.14 -7.5 (-6.02%) | 04-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 146 |
1-year : | 170.52 |
| Resists | First : | 125 |
Second : | 146 |
| Pivot price | 112.15 |
|||
| Supports | First : | 109.55 |
Second : | 100.01 |
| MAs | MA(5) : | 117.69 |
MA(20) : | 112.55 |
| MA(100) : | 106.63 |
MA(250) : | 63.56 |
|
| MACD | MACD : | 2.1 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 85.9 |
D(3) : | 86 |
| RSI | RSI(14): 54.8 |
|||
| 52-week | High : | 125 | Low : | 8.53 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CELC ] has closed below upper band by 27.4%. Bollinger Bands are 45.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 125.1 - 125.73 | 125.73 - 126.14 |
| Low: | 114.07 - 114.87 | 114.87 - 115.37 |
| Close: | 115.99 - 117.2 | 117.2 - 117.97 |
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Fri, 10 Apr 2026
Celcuity's Relentless Rally: From Under $10 To Over $120 In One Year - RTTNews
Wed, 08 Apr 2026
Why Celcuity (CELC) Is Up 5.5% After Reporting Wider 2025 Losses From Ongoing R&D Spending - Sahm
Tue, 07 Apr 2026
Why Celcuity (CELC) Is Up 5.5% After Reporting Wider 2025 Losses From Ongoing R&D Spending - simplywall.st
Sun, 05 Apr 2026
Is Celcuity (CELC) Still Attractive After Its Strong One Year Share Price Rally - Yahoo Finance
Wed, 01 Apr 2026
Is It Too Late To Consider Celcuity (CELC) After Its Strong Multi‑Year Share Price Run? - simplywall.st
Sun, 29 Mar 2026
Celcuity Inc. (NASDAQ:CELC) Q4 2025 earnings call transcript - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 10.5 (%) |
| Held by Institutions | 98 (%) |
| Shares Short | 9,130 (K) |
| Shares Short P.Month | 9,720 (K) |
| EPS | -3.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.07 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.3 % |
| Return on Equity (ttm) | -163.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -153 (M) |
| Levered Free Cash Flow | -96 (M) |
| PE Ratio | -30.91 |
| PEG Ratio | 0 |
| Price to Book value | 56.31 |
| Price to Sales | 0 |
| Price to Cash Flow | -36.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|